NTRB Nutriband Inc.
USHealthcareAs of 2026-07-10 16:00
Why NTRB matters now
Nutriband Inc. (NTRB) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.96 with -4.21% on the session and $36.0M in market capitalization; recent performance reads 1-month -15.94% and YTD -36.12%.
The latest financial table shown here is Q1 2026, with revenue of $433.4K, net income of $-1.2M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -12.4%.
The latest indexable market news headline is "Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.89
P/S
19.56
EV/EBITDA
-3.94
DCF Value
$-1.61
FCF Yield
-12.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
26.4%
Operating Margin
-452.6%
Net Margin
-448.4%
ROE
-112.6%
ROA
-117.3%
ROIC
-131.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $433.4K | $-1.2M | $-0.10 |
| Q4 2025 | $400.7K | $-968.1K | $-0.08 |
| FY 2025 | $2.0M | $-8.2M | $-2.58 |
| Q3 2025 | $346.1K | $-3.9M | $-0.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.85
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.